Camurus AB (STO:CAMX) and Braeburn Pharmaceuticals said today that the companies submitted a new drug application to the FDA for its weekly and monthly buprenorphine depots to treat opioid use disorder.
Braeburn also reported that it applied for priority review of its application, which could potentially shorten the company’s path to the market.
Get the full story at our sister site, Drug Delivery Business News.
The post Braeburn, Camurus seek FDA nod for buprenorphine depot appeared first on MassDevice.